Acromegaly;Acromégalie

Presse Medicale

Volumn 38, Issue 1, 2009, Pages 92-102

  Chanson, Philippe ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; GLUCOSE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; GROWTH HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; SHORT SURVEY; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADENOMA; AGE FACTORS; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PITUITARY NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 58049208258     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.09.016     Document Type: Short Survey

References (34)

1. Melmed S. Medical progress: acromegaly. N Engl J Med 355 24 (2006) 2558-2573
2. Chanson P., and Salenave S. Acromegaly. Orphanet J Rare Dis 3 (2008) 17
3. Holdaway I.M., and Rajasoorya C. Epidemiology of acromegaly. Pituitary 2 1 (1999) 29-41
4. Daly A.F., Rixhon M., Adam C., Dempegioti A., Tichomirowa M.A., and Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91 12 (2006) 4769-4775
5. Schneider H.J., Sievers C., Saller B., Wittchen H.U., and Stalla G.K. High prevalence of biochemical acromegaly in primary care patients with elevated insulin-like growth factor-1 levels. Clin Endocrinol 69 (2008) 432-435
6. Chanson P., Salenave S., and Orcel P. McCune-Albright syndrome in adulthood. Pediatr Endocr Rev 4 Suppl4 (2007) 453-463
7. Chanson P., Murat A., Cadiot G., and Calender A. Néoplasie endocrinienne multiple de type 1. In: Chanson P., and Young J. (Eds). Traité d'Endocrinologie (2007), Flammarion Médecine Sciences, Paris p1114-p1124
8. Bertherat J. Carney complex (CNC). Orphanet J Rare Dis 1 (2006) 21
9. Melmed S. Acromegaly. In: Melmed S. (Ed). The Pituitary. Malden, Mas (2002), Blackwell Science Inc, USA 419-454
10. Chanson P. Les conséquences de l'acromégalie (2001), Éditions Médicales Internationales, Cachan
11. Colao A., Ferone D., Marzullo P., and Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25 1 (2004) 102-152
12. Giustina A., Barkan A., Casanueva F.F., Cavagnini F., Frohman L., Ho K., et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85 2 (2000) 526-529
13. Cazabat L., Souberbielle J.C., and Chanson P. Dynamic tests for the diagnosis and assesment of treatment efficacy in acromegaly. Pituitary 11 (2008) 129-139
14. Dimaraki E.V., Jaffe C.A., DeMott-Friberg R., Chandler W.F., and Barkan A.L. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87 8 (2002) 3537-3542
15. Trainer P.J. Editorial: acromegaly-consensus, what consensus?. J Clin Endocrinol Metab 87 8 (2002) 3534-3536
16. Dekkers O.M., Biermasz N.R., Pereira A.M., Romijn J.A., and Vandenbroucke J.P. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93 1 (2008) 61-67
17. Holdaway I.M., Bolland M.J., and Gamble G.D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159 2 (2008) 89-95
18. Melmed S., Casanueva F.F., Cavagnini F., Chanson P., Frohman L., Grossman A., et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 87 9 (2002) 4054-4058
19. Melmed S., Casanueva F., Cavagnini F., Chanson P., Frohman L.A., Gaillard R., et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 153 6 (2005) 737-740
20. Biermasz N.R., van Dulken H., and Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 85 12 (2000) 4596-4602
21. Nomikos P., Buchfelder M., and Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152 3 (2005) 379-387
22. Barkan A.L., Halasz I., Dornfeld K.J., Jaffe C.A., Friberg R.D., Chandler W.F., et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82 10 (1997) 3187-3191
23. Barrande G., Pittino-Lungo M., Coste J., Ponvert D., Bertagna X., Luton J.P., et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85 10 (2000) 3779-3785
24. Castinetti F., Taieb D., Kuhn J.M., Chanson P., Tamura M., Jaquet P., et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90 8 (2005) 4483-4488
25. Newman C.B. Medical therapy for acromegaly. Endocrinol Metab Clin North Am 28 1 (1999) 171-190
26. Chanson P., Timsit J., and Harris A.G. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 25 5 (1993) 375-391
27. Freda P.U., Katznelson L., van der Lely A.J., Reyes C.M., Zhao S., and Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90 8 (2005) 4465-4473
28. Melmed S., Sternberg R., Cook D., Klibanski A., Chanson P., Bonert V., et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90 7 (2005) 4405-4410
29. Bevan J.S. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90 3 (2005) 1856-1863
30. Kopchick J.J., Parkinson C., Stevens E.C., and Trainer P.J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23 5 (2002) 623-646
31. Trainer P.J., Drake W.M., Katznelson L., Freda P.U., Herman-Bonert V., van der Lely A.J., et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342 16 (2000) 1171-1177
32. van der Lely A.J., Hutson R.K., Trainer P.J., Besser G.M., Barkan A.L., Katznelson L., et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358 9295 (2001) 1754-1759
33. Schreiber I., Buchfelder M., Droste M., Forssmann K., Mann K., Saller B., et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156 1 (2007) 75-82
34. Feenstra J., de Herder W.W., ten Have S.M., van den Beld A.W., Feelders R.A., Janssen J.A., et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365 9471 (2005) 1644-1646